Shares of Novo Nordisk A/S (ADR) (NYSE:NVO) ended Friday session in red amid volatile trading. The shares closed up -0.81 points or -1.46% at $54.61 with 1.50M shares getting traded. Post opening the session at $54.00, the shares hit an intraday low of $53.90 and an intraday high of $54.94 and the price vacillated in this range throughout the day. The 52-week high of (NVO) is $60.34 and the 52-week low is $46.17. The company has a market cap of $112.65B and the numbers of outstanding shares have been calculated to be 2.06B shares.
Novo Nordisk A/S (ADR) (NVO) engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity Care, and Biopharmaceuticals. The Diabetes and Obesity Care segment provides insulins, GLP-1 analog, obesity, and oral antidiabetic drugs, as well as other protein related products comprising glucagon, protein related delivery systems, and needles. The Biopharmaceuticals segment offers products in the areas of haemophilia care, growth hormone therapy, and hormone replacement therapy. The company markets and distributes its products through distributors and independent agents in North America, Europe, Japan and South Korea, China, Hong Kong, Taiwan, and other countries. Novo Nordisk A/S has a collaboration agreement with the Langer Laboratory. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
Shares of Novartis AG (ADR) (NYSE:NVS) ended Friday session in red amid volatile trading. The shares closed down -0.67 points or -0.82% at $72.88 with 3.38M shares getting traded. Post opening the session at $72.04, the shares hit an intraday low of $72.02 and an intraday high of $72.70 and the price vacillated in this range throughout the day. The 52-week high of (NVS) is $106.84 and the 52-week low is $70.64. The company has a market cap of $191.25B and the numbers of outstanding shares have been calculated to be 2.37million shares.
Novartis AG (ADR) (NVS) develops, manufactures, and markets a range of healthcare products worldwide. It operates through three segments: Pharmaceuticals, Alcon, and Sandoz. The Pharmaceuticals segment offers patented prescription medicines for oncology, neuroscience, retina, immunology and dermatology, respiratory, cardio-metabolic, established medicines, and cell and gene therapies. The Alcon segment provides eye care products, including ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses; medicines to treat chronic and acute diseases of the eye, and over-the-counter medicines for the eye; and contact lenses and lens care products. The Sandoz segment offers generic prescription medicines that include active ingredients and finished dosage forms of pharmaceuticals for dermatology, respiratory and ophthalmic, cardiovascular, metabolism, central nervous system, pain, gastrointestinal, and hormonal therapies; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products; and cytotoxic products for the hospital markets, as well as biotechnology manufacturing services to other companies. The company has collaboration and licensing agreements with Intellia Therapeutics for the discovery and development of new medicines using CRISPR genome editing technology; and with Caribou Biosciences for the development of drug discovery tools. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.
Shares of Opko Health Inc. (NYSE:OPK) ended Friday session in green amid volatile trading. The shares closed up 0.06 points or 0.55% at $11.05 with 7.51 M shares getting traded. Post opening the session at $11.15, the shares hit an intraday low of $11.02 and an intraday high of $11.47 and the price vacillated in this range throughout the day. The 52-week high of (OPK) is $19.20 and the 52-week low is $7.12. The company has a market cap of $6.06B and the numbers of outstanding shares have been calculated to be 545.70 million shares.
Opko Health Inc. (OPK) on March 16, 2016 announced dosing of the first subject in a Phase 1 single dose escalation study evaluating the safety and pharmacokinetics of a long-acting Oxyntomodulin (MOD-6031) in healthy, overweight or obese subjects. The study is intended to enroll 40 subjects in Israel.
Oxyntomodulin is a peptide hormone that acts as a dual GLP-1/Glucagon receptor agonist, with the potential to promote weight loss while improving glycemic control. Oxyntomodulin has been shown to increase energy expenditure, while reducing food intake and body weight, although its clinical utility is limited by its short circulating half-life. OPKO’s MOD-6031 has been designed, using a proprietary bi-functional hydrolysable linker, as a long-acting version of Oxyntomodulin for the treatment of Type II Diabetes and obesity, and is intended to reduce the required dosage frequency by prolonging the half-life, while improving the hormone’s pharmacokinetics and pharmacodynamics.